FDA delays meeting on Pfizer's COVID-19 vaccine for children under 5 to review more data

The FDA said the delay allows the agency time to review additional data.

vaccine for children younger than 5 that was originally scheduled to take place next week, raising questions about when they'll be able to get vaccinated against the deadly virus. The FDA said it wants to see more data from Pfizer before proceeding.in the U.S. that cannot yet get the vaccine.

But now, the FDA said it believes"additional information regarding the ongoing evaluation of a third dose should be considered." The delays gives the agency time to consider the additional data,"allowing for a transparent public discussion as part of our usual scientific and regulatory processes for COVID-19 vaccines."

"We will provide an update on timing for the advisory committee meeting once we receive additional data on a third dose in this age group from the company's ongoing clinical trial and have an opportunity to complete an updated evaluation," the FDA said in a statement. Early data from Pfizer showed that two low doses of its COVID vaccine, while safe, didn't offer enough immunity against the virus for kids of preschool age, the 2- to 4-year-olds.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

CBSNews /  🏆 87. in US

Canada Latest News, Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA postpones advisory panel meeting on Pfizer Covid-19 vaccine for younger childrenThe US Food and Drug Administration is postponing an advisory panel meeting on authorizing Pfizer’s Covid-19 vaccine in children under 5.
Read more »

Pfizer pulls FDA request for COVID-19 vaccine for kids under 5The company said it believes three doses “may provide a higher level of protection in this age group.”
Read more »

FDA Committee Delays Review of Pfizer-BioNTech's COVID-19 Vaccine for Young ChildrenFDA Committee Delays Review of Pfizer-BioNTech's COVID-19 Vaccine for Young Kids
Read more »

Pfizer Hits the Brakes on FDA Approval for COVID Vaccine for Kids Under 5The company wanted to see more data on how effective three doses would be for children ages 6 months to 4.
Read more »

Pfizer postpones FDA request for Covid vaccine for kids under 5The company said it believes three doses 'may provide a higher level of protection in this age group.'
Read more »